Cognitive and Functional Decline in Patients with Mild Alzheimer Dementia with or Without Comorbid Diabetes

Haya Ascher-Svanum, Yun Fei Chen, Ann Hake, Kristin Kahle-Wrobleski, Dara Schuster, David Kendall, Robert J. Heine

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose Although diabetes is recognized as a risk factor for the development of cognitive impairment and for accelerated progression to Alzheimer disease (AD), it is unclear whether patients with diabetes who have already progressed to AD have a different rate of cognitive and functional decline compared with that in those without diabetes. This post hoc exploratory analysis compared cognitive and functional decline over an 18-month period in patients with mild AD dementia with and without comorbid diabetes. Decline in quality of life was assessed as a secondary objective. Methods In a post hoc exploratory analysis, we analyzed data from the placebo groups of three 18-month, randomized, placebo-controlled trials of solanezumab and semagacestat in patients with AD. Data from patients with mild AD dementia (Mini-Mental State Examination [MMSE] score, 20-26) and comorbid diabetes at baseline were compared with data from patients with mild AD dementia without diabetes at baseline. Cognition was assessed using the 14-item AD Assessment Scale-Cognitive Subscale (ADAS-Cog14) and the MMSE. Functioning was assessed with the AD Cooperative Study-Activities of Daily Living Inventory (instrumental subset) (ADCS-iADL). Quality of life was assessed using the European Quality of Life-5 Dimensions scale, proxy version (proxy utility score and visual analog scale score), and the Quality of Life in AD scale, self-report and proxy (caregiver) versions. Group comparisons of changes from baseline to 18 months in cognitive, functional, and quality-of-life measures employed a repeated-measures model adjusted for propensity score, study, baseline cognition score (functional or quality of life), age, sex, level of education, genotype of the apolipoprotein E gene, and concurrent use of an acetylcholinesterase inhibitor or memantine. Findings At baseline, patients with mild AD dementia with and without diabetes did not significantly differ on the cognitive measures, but those without diabetes were functioning at a significantly higher level. At 18 months, compared with patients without diabetes, those with diabetes showed a numerically but statistically nonsignificantly lesser cognitive decline (least squares mean between-group differences: ADAS-Cog14 score, 1.61 [P = 0.21]; MMSE score, -0.40 [P = 0.49]) and a statistically significantly lesser functional decline (least squares mean between-group difference in ADCS-iADL score, -3.07; P = 0.01). The 2 groups did not differ on declines in the quality-of-life measures. Implications The present findings suggest that diabetes may influence the rate of functional decline among patients with mild AD dementia. These results require replication in studies that address the limitations of the present post hoc exploratory analysis and that explore the potential causes of the observed differences.

Original languageEnglish (US)
Pages (from-to)1195-1205
Number of pages11
JournalClinical Therapeutics
Volume37
Issue number6
DOIs
StatePublished - Jun 18 2015

Fingerprint

Alzheimer Disease
Quality of Life
Proxy
solanezumab
Cognitive Dysfunction
Least-Squares Analysis
N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide
Cognition
Placebos
Memantine
Propensity Score
Sex Education
Cholinesterase Inhibitors
Apolipoproteins E
Activities of Daily Living
Visual Analog Scale
Self Report
Caregivers
Randomized Controlled Trials
Genotype

Keywords

  • clinical trial
  • cognition
  • diabetes
  • functioning
  • Key words Alzheimer disease
  • quality of life

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Ascher-Svanum, H., Chen, Y. F., Hake, A., Kahle-Wrobleski, K., Schuster, D., Kendall, D., & Heine, R. J. (2015). Cognitive and Functional Decline in Patients with Mild Alzheimer Dementia with or Without Comorbid Diabetes. Clinical Therapeutics, 37(6), 1195-1205. https://doi.org/10.1016/j.clinthera.2015.01.002

Cognitive and Functional Decline in Patients with Mild Alzheimer Dementia with or Without Comorbid Diabetes. / Ascher-Svanum, Haya; Chen, Yun Fei; Hake, Ann; Kahle-Wrobleski, Kristin; Schuster, Dara; Kendall, David; Heine, Robert J.

In: Clinical Therapeutics, Vol. 37, No. 6, 18.06.2015, p. 1195-1205.

Research output: Contribution to journalArticle

Ascher-Svanum, H, Chen, YF, Hake, A, Kahle-Wrobleski, K, Schuster, D, Kendall, D & Heine, RJ 2015, 'Cognitive and Functional Decline in Patients with Mild Alzheimer Dementia with or Without Comorbid Diabetes', Clinical Therapeutics, vol. 37, no. 6, pp. 1195-1205. https://doi.org/10.1016/j.clinthera.2015.01.002
Ascher-Svanum, Haya ; Chen, Yun Fei ; Hake, Ann ; Kahle-Wrobleski, Kristin ; Schuster, Dara ; Kendall, David ; Heine, Robert J. / Cognitive and Functional Decline in Patients with Mild Alzheimer Dementia with or Without Comorbid Diabetes. In: Clinical Therapeutics. 2015 ; Vol. 37, No. 6. pp. 1195-1205.
@article{ace8c1a84a634290997b4356f5196df1,
title = "Cognitive and Functional Decline in Patients with Mild Alzheimer Dementia with or Without Comorbid Diabetes",
abstract = "Purpose Although diabetes is recognized as a risk factor for the development of cognitive impairment and for accelerated progression to Alzheimer disease (AD), it is unclear whether patients with diabetes who have already progressed to AD have a different rate of cognitive and functional decline compared with that in those without diabetes. This post hoc exploratory analysis compared cognitive and functional decline over an 18-month period in patients with mild AD dementia with and without comorbid diabetes. Decline in quality of life was assessed as a secondary objective. Methods In a post hoc exploratory analysis, we analyzed data from the placebo groups of three 18-month, randomized, placebo-controlled trials of solanezumab and semagacestat in patients with AD. Data from patients with mild AD dementia (Mini-Mental State Examination [MMSE] score, 20-26) and comorbid diabetes at baseline were compared with data from patients with mild AD dementia without diabetes at baseline. Cognition was assessed using the 14-item AD Assessment Scale-Cognitive Subscale (ADAS-Cog14) and the MMSE. Functioning was assessed with the AD Cooperative Study-Activities of Daily Living Inventory (instrumental subset) (ADCS-iADL). Quality of life was assessed using the European Quality of Life-5 Dimensions scale, proxy version (proxy utility score and visual analog scale score), and the Quality of Life in AD scale, self-report and proxy (caregiver) versions. Group comparisons of changes from baseline to 18 months in cognitive, functional, and quality-of-life measures employed a repeated-measures model adjusted for propensity score, study, baseline cognition score (functional or quality of life), age, sex, level of education, genotype of the apolipoprotein E gene, and concurrent use of an acetylcholinesterase inhibitor or memantine. Findings At baseline, patients with mild AD dementia with and without diabetes did not significantly differ on the cognitive measures, but those without diabetes were functioning at a significantly higher level. At 18 months, compared with patients without diabetes, those with diabetes showed a numerically but statistically nonsignificantly lesser cognitive decline (least squares mean between-group differences: ADAS-Cog14 score, 1.61 [P = 0.21]; MMSE score, -0.40 [P = 0.49]) and a statistically significantly lesser functional decline (least squares mean between-group difference in ADCS-iADL score, -3.07; P = 0.01). The 2 groups did not differ on declines in the quality-of-life measures. Implications The present findings suggest that diabetes may influence the rate of functional decline among patients with mild AD dementia. These results require replication in studies that address the limitations of the present post hoc exploratory analysis and that explore the potential causes of the observed differences.",
keywords = "clinical trial, cognition, diabetes, functioning, Key words Alzheimer disease, quality of life",
author = "Haya Ascher-Svanum and Chen, {Yun Fei} and Ann Hake and Kristin Kahle-Wrobleski and Dara Schuster and David Kendall and Heine, {Robert J.}",
year = "2015",
month = "6",
day = "18",
doi = "10.1016/j.clinthera.2015.01.002",
language = "English (US)",
volume = "37",
pages = "1195--1205",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "6",

}

TY - JOUR

T1 - Cognitive and Functional Decline in Patients with Mild Alzheimer Dementia with or Without Comorbid Diabetes

AU - Ascher-Svanum, Haya

AU - Chen, Yun Fei

AU - Hake, Ann

AU - Kahle-Wrobleski, Kristin

AU - Schuster, Dara

AU - Kendall, David

AU - Heine, Robert J.

PY - 2015/6/18

Y1 - 2015/6/18

N2 - Purpose Although diabetes is recognized as a risk factor for the development of cognitive impairment and for accelerated progression to Alzheimer disease (AD), it is unclear whether patients with diabetes who have already progressed to AD have a different rate of cognitive and functional decline compared with that in those without diabetes. This post hoc exploratory analysis compared cognitive and functional decline over an 18-month period in patients with mild AD dementia with and without comorbid diabetes. Decline in quality of life was assessed as a secondary objective. Methods In a post hoc exploratory analysis, we analyzed data from the placebo groups of three 18-month, randomized, placebo-controlled trials of solanezumab and semagacestat in patients with AD. Data from patients with mild AD dementia (Mini-Mental State Examination [MMSE] score, 20-26) and comorbid diabetes at baseline were compared with data from patients with mild AD dementia without diabetes at baseline. Cognition was assessed using the 14-item AD Assessment Scale-Cognitive Subscale (ADAS-Cog14) and the MMSE. Functioning was assessed with the AD Cooperative Study-Activities of Daily Living Inventory (instrumental subset) (ADCS-iADL). Quality of life was assessed using the European Quality of Life-5 Dimensions scale, proxy version (proxy utility score and visual analog scale score), and the Quality of Life in AD scale, self-report and proxy (caregiver) versions. Group comparisons of changes from baseline to 18 months in cognitive, functional, and quality-of-life measures employed a repeated-measures model adjusted for propensity score, study, baseline cognition score (functional or quality of life), age, sex, level of education, genotype of the apolipoprotein E gene, and concurrent use of an acetylcholinesterase inhibitor or memantine. Findings At baseline, patients with mild AD dementia with and without diabetes did not significantly differ on the cognitive measures, but those without diabetes were functioning at a significantly higher level. At 18 months, compared with patients without diabetes, those with diabetes showed a numerically but statistically nonsignificantly lesser cognitive decline (least squares mean between-group differences: ADAS-Cog14 score, 1.61 [P = 0.21]; MMSE score, -0.40 [P = 0.49]) and a statistically significantly lesser functional decline (least squares mean between-group difference in ADCS-iADL score, -3.07; P = 0.01). The 2 groups did not differ on declines in the quality-of-life measures. Implications The present findings suggest that diabetes may influence the rate of functional decline among patients with mild AD dementia. These results require replication in studies that address the limitations of the present post hoc exploratory analysis and that explore the potential causes of the observed differences.

AB - Purpose Although diabetes is recognized as a risk factor for the development of cognitive impairment and for accelerated progression to Alzheimer disease (AD), it is unclear whether patients with diabetes who have already progressed to AD have a different rate of cognitive and functional decline compared with that in those without diabetes. This post hoc exploratory analysis compared cognitive and functional decline over an 18-month period in patients with mild AD dementia with and without comorbid diabetes. Decline in quality of life was assessed as a secondary objective. Methods In a post hoc exploratory analysis, we analyzed data from the placebo groups of three 18-month, randomized, placebo-controlled trials of solanezumab and semagacestat in patients with AD. Data from patients with mild AD dementia (Mini-Mental State Examination [MMSE] score, 20-26) and comorbid diabetes at baseline were compared with data from patients with mild AD dementia without diabetes at baseline. Cognition was assessed using the 14-item AD Assessment Scale-Cognitive Subscale (ADAS-Cog14) and the MMSE. Functioning was assessed with the AD Cooperative Study-Activities of Daily Living Inventory (instrumental subset) (ADCS-iADL). Quality of life was assessed using the European Quality of Life-5 Dimensions scale, proxy version (proxy utility score and visual analog scale score), and the Quality of Life in AD scale, self-report and proxy (caregiver) versions. Group comparisons of changes from baseline to 18 months in cognitive, functional, and quality-of-life measures employed a repeated-measures model adjusted for propensity score, study, baseline cognition score (functional or quality of life), age, sex, level of education, genotype of the apolipoprotein E gene, and concurrent use of an acetylcholinesterase inhibitor or memantine. Findings At baseline, patients with mild AD dementia with and without diabetes did not significantly differ on the cognitive measures, but those without diabetes were functioning at a significantly higher level. At 18 months, compared with patients without diabetes, those with diabetes showed a numerically but statistically nonsignificantly lesser cognitive decline (least squares mean between-group differences: ADAS-Cog14 score, 1.61 [P = 0.21]; MMSE score, -0.40 [P = 0.49]) and a statistically significantly lesser functional decline (least squares mean between-group difference in ADCS-iADL score, -3.07; P = 0.01). The 2 groups did not differ on declines in the quality-of-life measures. Implications The present findings suggest that diabetes may influence the rate of functional decline among patients with mild AD dementia. These results require replication in studies that address the limitations of the present post hoc exploratory analysis and that explore the potential causes of the observed differences.

KW - clinical trial

KW - cognition

KW - diabetes

KW - functioning

KW - Key words Alzheimer disease

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=84931004209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931004209&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2015.01.002

DO - 10.1016/j.clinthera.2015.01.002

M3 - Article

VL - 37

SP - 1195

EP - 1205

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 6

ER -